1. Articles in category: Genomics

    1-24 of 224 1 2 3 4 5 6 7 8 9 10 »
    1. LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      LMO1 polymorphisms reduce neuroblastoma risk in Chinese children: a two-center case-control study.

      Oncotarget. 2017 Sep 12;8(39):65620-65626

      Authors: Zhang J, Lin H, Wang J, He J, Zhang D, Qin P, Yang L, Yan L

      Abstract Previous genome-wide association and validation studies suggest that LIM domain only 1 (LMO1) gene polymorphisms affect neuroblastoma susceptibility.

      Read Full Article
    2. Zebrafish as a model to study neuroblastoma development.

      Zebrafish as a model to study neuroblastoma development.

      Cell Tissue Res. 2017 Oct 13;:

      Authors: Casey MJ, Stewart RA

      Abstract Neuroblastoma is a pediatric solid tumor arising from embryonic neural crest progenitor cells that normally generate the peripheral sympathetic nervous system.

      Read Full Article
      Mentions: ALK
    3. NIH Funds Pediatric Data Resource Center.

      NIH Funds Pediatric Data Resource Center.

      Cancer Discov. 2017 Oct 11;:

      Authors:

      Abstract Children's Hospital of Philadelphia will lead a collaborative effort-funded with $14.8 million from the NIH-to pool genomic and phenotypic data from tens of thousands of patients to study the causes of pediatric cancer and structural birth defects.

      PMID: 29021134 [PubMed - as supplied by publisher]

      Read Full Article
    4. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.

      Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.

      BMC Syst Biol. 2017 Oct 03;11(Suppl 5):92

      Authors: Yang XH, Tang F, Shin J, Cunningham JM

      Abstract BACKGROUND: Previous studies suggested that cancer cells possess traits reminiscent of the biological mechanisms ascribed to normal embryonic stem cells (ESCs) regulated by MYC and Polycomb repressive complex 2 (PRC2).

      Read Full Article
      Mentions: MYCN
    5. Researchers Identify Gene Variants Linked to a High-Risk Children's Cancer

      Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery, in the MMP20 gene, may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    6. Researchers identify gene variants linked to a high-risk children's cancer

      Researchers identify gene variants linked to a high-risk children's cancer

      ( Children's Hospital of Philadelphia ) Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing subtypes of neuroblastoma.

      Read Full Article
      Mentions: Genetics
    7. Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.

      Nat Commun. 2017 Sep 18;8(1):569

      Authors: Chang X, Zhao Y, Hou C, Glessner J, McDaniel L, Diamond MA, Thomas K, Li J, Wei Z, Liu Y, Guo Y, Mentch FD, Qiu H, Kim C, Evans P, Vaksman Z, Diskin SJ, Attiyeh EF, Sleiman P, Maris JM, Hakonarson H

      Read Full Article
      Mentions: MYCN
    8. Kids First Data Resource Center set to ‘unlock potential’ of genomic data in pediatric cancer

      The NIH established the Kids First Data Resource Center, a pediatric cancer and rare disease data program that will enable clinicians and researchers to collaborate and access multiple genomic datasets.The resource center — the first of its kind in the pediatric research community — is designed to create a centralized, cloud-based database and discovery portal of clinical and genetic sequence data from various pediatric cancers and structural birth defects cohorts, such as congenital heart defects, hearing loss and cleft palate. The program also will develop analytical tools to provide access to this large-scale data for use in the discovery of novel ...

      Read Full Article
      Mentions: Hearing Loss
    9. Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects

      Children's Hospital of Philadelphia to Lead New Pediatric Data Resource Center for Research in Childhood Cancer and Structural Birth Defects

      PHILADELPHIA, Aug. 15, 2017 /PRNewswire-USNewswire/ -- The Center for Data Driven Discovery in Biomedicine at Children's Hospital of Philadelphia (CHOP) will lead a new, collaborative effort funded by the National Institutes of Health Common Fund to discover the causes of pediatric cancer...

      Read Full Article
    10. New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      New Tumor Database Deployed to Battle Childhood Cancer at UC Santa Cruz

      The Treehouse Childhood Cancer Initiative researchers at UC Santa Cruz Genomics Institute and the St. Baldrick's Foundation are making a 11,000+ tumor database available for use by all researchers in the pediatric cancer community and beyond in our continued battle to take childhood back from cancer. The database contains RNA-Seq gene expression data, as well as age, disease, and sex.

      Read Full Article
      Mentions: Genetics
    11. NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH Trial to Test Targeted Therapies

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers Posted: July 24, 2017 240-760-6600 Credit: National Cancer Institute Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial.

      Read Full Article
      Mentions: Treatment COG
    12. MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      MOlecular Screening for CAncer Treatment Optimization (MOSCATO-01) in pediatric patients: A single institutional prospective molecular stratification trial.

      Clin Cancer Res. 2017 Jul 21;:

      Authors: Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Galmiche L, Meurice G, Minard-Colin V, Grill J, Brugières L, Dufour C, Gaspar N, Michiels S, Vassal G, Soria JC, Geoerger B

      Read Full Article
      Mentions: Treatment
    13. NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

      The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

      Read Full Article
      Mentions: Treatment COG
    14. Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients.

      Clin Cancer Res. 2017 Jul 14;:

      Authors: Van Roy N, Van der Linden M, Menten B, Dheedene A, Vandeputte C, Van Dorpe J, Laureys G, Renard M, Sante T, Lammens T, De Wilde B, Speleman F, De Preter K

      Read Full Article
      Mentions: MYCN ATRX
    15. Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR 1/2/3/4 Mutations

      Conditions :   Advanced Malignant Solid Neoplasm;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Stage III Childhood Non-Hodgkin Lymphoma;   Stage IV Childhood Non-Hodgkin Lymphoma Interventions :   Other: Laboratory Biomarker Analysis;   Drug: pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493;   Other: Pharmacological Study Sponsor :   National Cancer Institute (NCI) Not yet recruiting - verified June 2017

      Read Full Article
      Mentions: Refractory
    16. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Pediatr Hematol Oncol. 2017 Jun 29;:1-21

      Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M

      Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.

      Read Full Article
      Mentions: MYCN
    17. New research points to potential targeted treatments of neuroblastoma tumours

      New research points to potential targeted treatments of neuroblastoma tumours

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine.

      The findings lay the groundwork for developing more targeted treatments for...

      Read Full Article
      Mentions: MYCN
    18. Potential for more targeted treatments of neuroblastoma tumors

      Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

      Read Full Article
      Mentions: MYCN
    1-24 of 224 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) MYCN